The study by Cameron (2009) suggests that one of the most effective ways of lowering the incidence of mortality from neutropenia is educating the patients. The paper suggests that letting the patients know what the signs of (febrile) neutropenia are and how they can be recognized will allow patients to understand when to contact their healthcare provider to ensure that they receive treatment for the condition as soon as possible, lowering the mortality of the condition. There are many different side-effects of chemotherapy that can be confused with the development of neutropenia (Nirenburg et al, 2006), but patients should be informed to check for a fever over 37.5C, mouth ulcers and general malaise (Cameron, 2009). The study by Cameron (2009) then goes on to suggest that educating the healthcare providers when the risk of neutropenia is highest and the white blood cell count is likely to be lowest is most imminent during the chemotherapy course. It has been suggested that most chemotherapy treatments are most effective and thus neutropenia risk is highest at the 10-14 day stage of treatment (Hall, 2005) and thus providers and patients alike would benefit from understanding this fact. However, different chemotherapies have different apexes, and thus both patient and provider should understand that the risks may be different dependant on type of treatment received (Cameron, 2009). It has also been shown that the duration of febrile neutropenia in patients with solid tumours can be predicted (Matias et al, 2010). The only data needed to provide this information to a patient or a member of healthcare staff is the aggressiveness of the cytotoxic agents used in that chemotherapy (Matias et al, 2010). This has the benefit of allowing both patients and healthcare staff to predict the severity and duration of neutropenia before the chemotherapy is started, and if the system was imposed thoroughly it could lead to a reduction in the cases of neutropenia. It could also allow physicians to make more informed choices about the chemotherapy regimen chosen for the patients which could reduce the chances of neutropenia. There is more evidence for the development of a risk assessment tool for those at risk that may help to reduce the rates of chemotherapy-related neutropenia. Donohue (2006) has shown that giving those at risk a colony-stimulating factor (CSF) before chemotherapy is started can give the patients an increased risk of survival and reduced risks of neutropenia (p349). This is more evidence that education would be a useful factor in many situations, as nurses and physicians would need to be educated in using the risk assessment tool, and then understand the results given by this tool. However, after this it would decrease rates of neutropenia in many patients (p350) and thus achieve the goals set out by the PICO-formatted question outlined above. Crawford et al (2004) have also shown that there are assorted risk-factors for chemotherapy patients. It has been shown that 'combined cyclophosphamide, methotrexate, and 5-fluorouracil is less toxic than AC or combined cyclophosphamide, doxorubicin, and 5-fluorouraci
Cite this document
(“Neutropenia in the Chemotherapy Patient Essay Example | Topics and Well Written Essays - 1000 words”, n.d.)
Retrieved from https://studentshare.net/nursing/51126-neutropenia-in-the-chemotherapy-patient
(Neutropenia in the Chemotherapy Patient Essay Example | Topics and Well Written Essays - 1000 Words)
“Neutropenia in the Chemotherapy Patient Essay Example | Topics and Well Written Essays - 1000 Words”, n.d. https://studentshare.net/nursing/51126-neutropenia-in-the-chemotherapy-patient.
Cited: 0 times
Decreasing Rates of Neutropenia in the Chemotherapy Patient Student School Course Number and Title Professor Session Decreasing Rates of Neutropenia in the Chemotherapy Patient Literature Review A review of the literature suggests that 'not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles' (Cameron, 2009, p101), suggesting that it is important to understand the condition, how it arises and methods that can be used to lower the rate of neutropenia in the chemotherapy patient…
He was admited for intravenous iron-sucrose adminsitration. The patient was first given a challenge dose to ascertain any posssiblity of anaphylactic reaction. It was negative. However, even after starting the treatment, I monitored the patient closely. Within 5 minutes after starting the drip, the patient began to complian of giddiness.
In addition to the uncontrollable growth of cells once the body is inflicted with cancer these cells grow at an explosive rate. This is one of the reasons the disease is so difficult to manage if it is not detected at an early stage. Even in the cases where the cancer has been detected early it is still difficult to treat and manage.
The research that follows shows that often times the problem is that staff do not understand how to talk to these patients as well as the difficult issue of when to talk to them. Recent research indicates that the information needs of the breast cancer patient include early information in an effort to improve their ability to make adequate treatment decisions (Cawley, Kostic, & Cappello, 1990).
This patient had stage 1 carcinoma of the breast with no lymph node involvement at presentation. The patient underwent FEC chemotherapy for this. The chemotherapy was uneventful except for some nausea that was managed well with antiemetic medications. This reflective essay is a journey through the cytotoxic chemotherapy of this particular patient from the perspectives of a practitioner with the aim and purpose to revisit the competencies and knowledge that are necessary to manage such a patient undergoing cytotoxic chemotherapy.
For the uninitiated, the very mention of the word conjures up gruesome images of sickness and diarrhea, oral problems, hair and skin allergies, and irreversible damage to blood cells (Cancerhelp.org.uk, 2006). Despite side-effects, Chemotherapy is an intrinsic ritual of Cancer treatment, and as a member of the Nursing profession, my job is to present best possible solutions for the Chemotherapy problem addressed in this particular case study: Cancer-related fatigue (CRF) as defined by the National Comprehensive Cancer Network "is a persistent, subjective sense of tiredness related to cancer treatment that interferes with usual functioning" (NCCN, 2005).
They have all the right to know everything. That is why there are consultations with the doctor. However, according to Wilson , a study showed that patients forget half the doctor’s advise after five minutes they have left the consultation room. This is quite an
The condition can involve any of the lineages of the myeloid system, including megakaryotic, granulocytic and erythrocytic hematopoiesis and is considered to be a premalignant condition with the potential to progress to acute myeloid
lnerability where the face to face encounter between the patients and the nurses becomes the arena for the authentic meeting persons where the integrity, dignity and humanity of the both nurses and the patients are respected and affirmed. Being such, nursing care is not just
The following research will describe drugs which are being widely used in the chemotherapy of cancer. Antibiotics used in cancer are formed from agents such as doxorubicin, daunorubicin, dactinomycin and mitomycin. All these above mentioned drugs have an important role to play in the eradication of cancer from the body.